Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Reversible cerebral vasoconstriction syndrome in a methylphenidate-treated patient: a case report.
BMC Neurol
December 2024
Pharmacovigilance, Pharmacoepidemiology and Drug Information Centre, Department of Clinical Pharmacology, Rennes University Hospital, Rennes, 35033, France.
Background: Reversible cerebral vasoconstriction syndrome (RCVS) is characterized by severe headaches, often thunderclap headaches, and a multifocal constriction of the cerebral arteries. Although RCVS can occur spontaneously, some cases occur after exposure to drugs. We describe the first case of RCVS in which methylphenidate, a drug with vasoconstrictive properties, is the only suspected drug.
View Article and Find Full Text PDFDepression of Ca1.2 activation and expression in mast cells ameliorates allergic inflammation diseases.
J Pharm Anal
November 2024
Department of Pharmaceutical Analysis, School of Pharmacy, Xi'an Jiaotong University, Xi'an, 710061, China.
Allergic inflammation is closely related to the activation of mast cells (MCs), which is regulated by its intracellular Ca level, but the intake and effects of the intracellular Ca remain unclear. The Ca influx is controlled by members of Ca channels, among which calcium voltage-gated channel subunit alpha1 C (Ca1.2) is the most robust.
View Article and Find Full Text PDFAn L-type calcium channel blocker nimodipine exerts anti-fibrotic effects by attenuating TGF-β1 induced calcium response in an in vitro model of thyroid eye disease.
Eye Vis (Lond)
September 2024
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology Visual Science, Guangzhou, 510060, China.
Article Synopsis
- - The study investigates the role of calcium (Ca) signaling in tissue fibrosis related to thyroid eye disease (TED), a serious autoimmune disorder affecting vision, and evaluates the therapeutic potential of nimodipine, an L-type calcium channel (LTCC) inhibitor.
- - Researchers used primary cultures of orbital fibroblasts from TED patients and healthy donors, employing various techniques like RT-qPCR and flow cytometry to measure changes in gene expression and cell behavior in response to TGF-β1, a fibrosis-inducing factor.
- - Results showed that nimodipine effectively blocked the Ca response triggered by TGF-β1, leading to a decrease in fibrogenic markers such as α-SMA and collagen types I and
Simultaneous use of venlafaxine and calcium channel blockers on tolerance to morphine: The role of mitochondrial damage and oxidative stress in the brain.
Pharmacol Biochem Behav
December 2024
Department of Pharmacology, School of Medicine, Dezful University of Medical Sciences, Dezful, Iran. Electronic address:
Background: One of the reasons for tolerance to morphine is increased oxidative stress and dysfunction of cell mitochondria in the hippocampus. Venlafaxine and calcium channel blockers can protect mitochondrial function. The investigation of the role of mitochondrial damage and oxidative stress in the simultaneous use of venlafaxine and calcium channel blockers on the acute analgesic effects of morphine and the induction of tolerance to its effects in mice was assessed.
View Article and Find Full Text PDF[RCVS: case-study and role of substance abuse, Covid and psychotropic drugs].
Tijdschr Psychiatr
August 2024
Reversible cerebral vasoconstriction syndrome (RCVS) is a condition defined by severe sudden-onset headaches, typically ‘thunderclap’ headaches, caused by multifocal cerebral vasoconstriction. Various triggers have been described, including illegal substances, medication and infections. We observed a 27 year old man that suddenly developed severe headaches during admission to a psychiatric ward, where RCVS was diagnosed as most likely clinical cause.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!